Literature DB >> 21396743

Amodiaquine analogues containing NO-donor substructures: synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria.

Massimo Bertinaria1, Stefano Guglielmo, Barbara Rolando, Marta Giorgis, Cristina Aragno, Roberta Fruttero, Alberto Gasco, Silvia Parapini, Donatella Taramelli, Yuri C Martins, Leonardo J M Carvalho.   

Abstract

The synthesis and physico-chemical properties of novel compounds obtained by conjugation of amodiaquine with moieties containing either furoxan or nitrooxy NO-donor substructures are described. The synthesised compounds were tested in vitro against both the chloroquine sensitive, D10 and the chloroquine resistant, W-2 strains of Plasmodium falciparum (P. falciparum). Most of the compounds showed an antiplasmodial activity comparable to that of the parent drug. By comparing the activities of simple related structures devoid of the ability to release NO, it appears that the contribution of NO to the antiplasmodial action in vitro is marginal. All the compounds were able to relax rat aorta strips with a NO-dependent mechanism, thus showing their capacity to release NO in the vessels. A preliminary in vivo study using Plasmodium berghei ANKA-infected mice showed a trend for prolonged survival of mice with cerebral malaria treated with compound 40, which is potent and fast amodiaquine-derived NO-donor, when compared with amodiaquine alone or with compound 31, a milder NO-donor. The two compounds showed in vivo antiplasmodial activity similar to that of amodiaquine.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21396743     DOI: 10.1016/j.ejmech.2011.02.029

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

Review 1.  Cerebral malaria: we have come a long way.

Authors:  Henry J Shikani; Brandi D Freeman; Michael P Lisanti; Louis M Weiss; Herbert B Tanowitz; Mahalia S Desruisseaux
Journal:  Am J Pathol       Date:  2012-09-25       Impact factor: 4.307

2.  A furoxan-amodiaquine hybrid as a potential therapeutic for three parasitic diseases().

Authors:  Bryan T Mott; Ken Chih-Chien Cheng; Rajarshi Guha; Valerie P Kommer; David L Williams; Jon J Vermeire; Michael Cappello; David J Maloney; Ganesha Rai; Ajit Jadhav; Anton Simeonov; James Inglese; Gary H Posner; Craig J Thomas
Journal:  Medchemcomm       Date:  2012-12       Impact factor: 3.597

3.  NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria.

Authors:  Massimo Bertinaria; Pamela Orjuela-Sanchez; Elisabetta Marini; Stefano Guglielmo; Anthony Hofer; Yuri C Martins; Graziela M Zanini; John A Frangos; Alberto Gasco; Roberta Fruttero; Leonardo J M Carvalho
Journal:  J Med Chem       Date:  2015-09-24       Impact factor: 7.446

4.  Leishmanicidal activities of novel synthetic furoxan and benzofuroxan derivatives.

Authors:  Luiz Antônio Dutra; Letícia de Almeida; Thais G Passalacqua; Juliana Santana Reis; Fabio A E Torres; Isabel Martinez; Rosangela Gonçalves Peccinini; Chung Man Chin; Konstantin Chegaev; Stefano Guglielmo; Roberta Fruttero; Marcia A S Graminha; Jean Leandro dos Santos
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

5.  A new hypothesis on the manifestation of cerebral malaria: the secret is in the liver.

Authors:  Yuri Chaves Martins; Cláudio Tadeu Daniel-Ribeiro
Journal:  Med Hypotheses       Date:  2013-08-13       Impact factor: 1.538

Review 6.  Introducing New Antimalarial Analogues of Chloroquine and Amodiaquine: A Narrative Review.

Authors:  Arezoo Rafiee Parhizgar; Azar Tahghighi
Journal:  Iran J Med Sci       Date:  2017-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.